Skip to main content
PolicySpeak
← All files
IP

Insud Pharma

Company · Spain · EU Transparency Register 512399952821-80

1
position filed
in the 673 files tracked
1
legislative file
of 673 tracked
1
with a full position paper
attached to a submission

Counts here are a floor, never a total: they cover the 673 consultation files tracked so far (58,314 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.

Who they are

Among the 1216 companies & groups on this site, they rank #1025 by legislative files engaged, a count of participation, not a measure of influence.

0.3
declared lobbying FTE
self-declared
€10K+
declared costs / yr (floor)
0
EP accreditations
as declared to the register
2024
in the register since

Declares membership of

  • Medicines for Europe (M4E)
  • International Generics and Biosimilar Association (IGBA)
  • Real Instituto Elcano (miembro Comisión Ejecutiva)

Self-declared to the EU Transparency Register (snapshot 20 Oct 2026).

Register category
Companies & groups
Registered as
INSUD PHARMA
Head office
Madrid, Spain

Self-declared to the EU Transparency Register (snapshot 20 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.

Track Insud in PolicySpeak: request access →

Follow Insud Pharma

An email when this organization files on a consultation we publish.

We use your email for these updates, and PolicySpeak may contact you about the product. Unsubscribe in one click. Privacy policy.

Work at Insud Pharma? so we know who speaks for it.

Their record over time

Insud Pharma filed 1 position on 26 Feb 2025, across 1 of the 673 legislative files tracked here, attaching a full position paper 1 time.

What they argued

Critical Medicines Actfiled 26 Feb 2025PDFsource

CIF: B83628248 VAT: ESB83628248 Inscrita en el Registro Mercantil de Madrid / Tomo 18.722 / Folio 180 / Sección 8ª / Hoja M-326.179 / Inscripción 1ª Domicilio social: Manuel Pombo Angulo, 28 3ª planta 28050 Madrid - España The Critical Medicines Act must lead to a resilient, competitive, and sustainable off-patent pharmaceutical industry.

Opening of the attached position paper · the full paper is on the Commission’s record (source link above)

Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.

Put Insud Pharma next to another organization. Same files, same register facts, side by side. Compare →

Is this your organization?

Everything on this page comes from Insud Pharma’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.

Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.